Literature DB >> 19966052

Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta.

Mohammad M Khan1, Yuchuan Liu, Munir E Khan, Megan L Gilman, Sabina T Khan, Michael Bromberg, Robert W Colman.   

Abstract

Inflammatory bowel disease and arthritis are associated with contact activation that results in cleavage of kininogen to form high molecular weight kininogen (HKa) and bradykinin. We have previously demonstrated that HKa can stimulate inflammatory cytokine and chemokine secretion from human monocytes. We now show that HKa can upregulate tissue factor antigen and procoagulant activity on human monocytes as a function of time (1-4 h) and HKa concentration (75-900 nM). The amino acid sequence responsible to block HKa effects is G440-H455. The HKa receptor macrophage-1 (Mac-1; CD11b18) is the binding site as shown by inhibition by a monoclonal antibody to CD11b/18. Chemical inhibitors of JNK, ERK, and p38 signaling pathways block cell signaling, as does an inhibitor to the transcription factor NF-kappaB. A combination of monoclonal antibodies to TNF-alpha and IL-1beta but neither alone inhibited the HKa induction of tissue factor. These results suggest that HKa mimics LPS by triggering a paracrine pathway in monocytes that depends on TNF-alpha and IL-1beta. Antibodies to kininogen or peptidomimetics might be a useful and safe therapy in inflammatory diseases or sepsis involving cytokines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966052      PMCID: PMC2822566          DOI: 10.1152/ajpheart.00825.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  34 in total

1.  Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.

Authors:  R W Colman; B A Jameson; Y Lin; D Johnson; S A Mousa
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

Review 2.  TNF signaling in vascular endothelial cells.

Authors:  L A Madge; J S Pober
Journal:  Exp Mol Pathol       Date:  2001-06       Impact factor: 3.362

3.  Inhibition of tissue factor synthesis by disruption of ERK kinases and PKC signaling pathways in human vascular SMCs.

Authors:  J M Xuereb; P Sié; B Boneu; J Constans
Journal:  Thromb Haemost       Date:  2000-07       Impact factor: 5.249

4.  Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways.

Authors:  Masato Eto; Toshiyuki Kozai; Francesco Cosentino; Hana Joch; Thomas F Lüscher
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

Review 5.  TNF receptor subtype signalling: differences and cellular consequences.

Authors:  David J MacEwan
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

Review 6.  Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis.

Authors:  Rafal Pawlinski; Nigel Mackman
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

7.  Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo.

Authors:  Masayasu Kawasaki; Toshinaga Maeda; Kazuyoshi Hanasawa; Iwao Ohkubo; Tohru Tani
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

8.  The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells.

Authors:  Mausumee Guha; Nigel Mackman
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157

9.  Disease-specific screening for deep venous thrombosis and pulmonary thromboembolism using plasma D-dimer values after total knee arthroplasty.

Authors:  Teruhito Yoshitaka; Nobuhiro Abe; Hiroshi Minagawa; Hirokazu Date; Yoshimasa Sakoma; Keiichiro Nishida; Toshifumi Ozaki
Journal:  Mod Rheumatol       Date:  2008-05-08       Impact factor: 3.023

10.  Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats.

Authors:  Irma Isordia-Salas; Robin A Pixley; Fengling Li; Irma Sainz; R Balfour Sartor; Albert Adam; Robert W Colman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-07       Impact factor: 4.052

View more
  7 in total

Review 1.  Review: the Multiple Roles of Monocytic Microparticles.

Authors:  Ahmad Tarmizi Abdul Halim; Nur Azrah Fazera Mohd Ariffin; Maryam Azlan
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

2.  Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.

Authors:  Mohammad M Khan; Steven D Douglas; Tami D Benton
Journal:  J Neuroimmunol       Date:  2011-11-23       Impact factor: 3.478

3.  High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Malgorzata Kasztan; Michael W Henderson; Patrick Ellsworth; Parker Ross Davis; Kathryn J Wilson; Brandi Reeves; Nigel S Key; Sidney Strickland; Keith McCrae; David M Pollock; Rafal Pawlinski
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

4.  Longitudinal study of circulating protein biomarkers in inflammatory bowel disease.

Authors:  Emilie Viennois; Mark T Baker; Bo Xiao; Lixin Wang; Hamed Laroui; Didier Merlin
Journal:  J Proteomics       Date:  2014-09-16       Impact factor: 4.044

5.  A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.

Authors:  Victoria Marcu-Malina; Alexandra Balbir-Gurman; Rima Dardik; Yolanda Braun-Moscovici; Michael J Segel; Ilan Bank
Journal:  Front Immunol       Date:  2014-09-08       Impact factor: 7.561

6.  Automatic gene prioritization in support of the inflammatory contribution to Alzheimer's disease.

Authors:  Stephanie K Furniss; Robert Yao; Graciela Gonzalez
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2014-04-07

Review 7.  CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.

Authors:  Xiaomin Zhang; Lingling Zhu; Hui Zhang; Shanshan Chen; Yang Xiao
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.